Racquel Bracken - Jun 17, 2021 Form 3 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role
Director
Signature
By: /s/ Andrew Gengos, Attorney-in-Fact
Stock symbol
CYT
Transactions as of
Jun 17, 2021
Transactions value $
$0
Form type
3
Date filed
6/17/2021, 09:34 PM
Next filing
Feb 24, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CYT Stock Option (Right to Buy) Jun 17, 2021 Common Stock 17.3K $18.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest in full on the earlier of (a) June 17, 2022 and (b) the next annual meeting of stockholders that follows June 17, 2021, in each case subject to the Reporting Person's continued service on the Issuer's board of directors through the applicable vesting date.
F2 Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported shares for the sole benefit of the Management Company and must exercise the reported shares solely upon the direction of the Management Company, which is entitled to the shares. The Management Company may be deemed the indirect beneficial owner of the reported shares, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares through her interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of her pecuniary interest therein.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney